JnJ wins USFDA approval for subcutaneous Rybrevant Faspro for EGFR-Mutated NSCLC
Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for…